Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
暂无分享,去创建一个
Christopher B. Miller | J. Downing | S. Shurtleff | M. Relling | Cheng Cheng | D. Campana | C. Pui | D. Gerhard | I. Radtke | R. Clifford | Jing Ma | C. Mullighan | Wenjian Yang | S. Hunger | C. Willman | M. Borowitz | X. Su | Jinghui Zhang | B. Schulman | L. A. Phillips | M. Devidas | Malcolm A. Smith | G. Reaman | W. Carroll | Wei Liu | R. Harvey | I. Chen | W. Bowman | Letha A. Phillips | C. Miller | Letha A A Phillips
[1] R. Arceci,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .
[2] W. Westerhof,et al. Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short‐term NB‐UVB phototherapy in the treatment of non‐segmental vitiligo: a left–right comparative study , 2008, Photodermatology, photoimmunology & photomedicine.
[3] James R. Downing,et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.
[4] L. Naldi,et al. Randomized controlled trial comparing the effectiveness of 308‐nm excimer laser alone or in combination with topical hydrocortisone 17‐butyrate cream in the treatment of vitiligo of the face and neck , 2008, The British journal of dermatology.
[5] Rob Pieters,et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. , 2008, Cancer cell.
[6] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[7] T. Hubbard,et al. Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks , 2008, Cell.
[8] Christopher B. Miller,et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.
[9] Leslie L Robison,et al. Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.
[10] Carl W. Miller,et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. , 2007, Blood.
[11] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[12] J. Hehir-Kwa,et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression , 2007, Leukemia.
[13] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[14] R. Tibshirani,et al. On testing the significance of sets of genes , 2006, math/0610667.
[15] R. Tibshirani,et al. Prediction by Supervised Principal Components , 2006 .
[16] H. Cavé,et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. , 2006, Haematologica.
[17] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Relling,et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia , 2005, Cancer.
[19] Cheng Cheng,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.
[20] Jeanne Kowalski,et al. Microarray and Serial Analysis of Gene Expression Analyses Identify Known and Novel Transcripts Overexpressed in Hematopoietic Stem Cells , 2004, Cancer Research.
[21] R. Tibshirani,et al. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.
[22] J. Downing,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[23] C. Garvie,et al. Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP). , 2003, Nucleic acids research.
[24] E. Cook,et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Rebollo,et al. Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies , 2003, Immunology and cell biology.
[26] G. Gustafsson,et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92 , 2002, Leukemia.
[27] C. Chabannon,et al. Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage. , 2001, Blood.
[28] F. Behm,et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital , 2000, Leukemia.
[29] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[30] A. Fisher,et al. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. , 2000, Genes & development.
[31] D. Nemazee,et al. B‐cell antigen receptor competence regulates B‐lymphocyte selection and survival , 2000, Immunological reviews.
[32] A. Look,et al. Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse , 1999 .
[33] H. Sather,et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.
[34] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[35] C. Pratt,et al. St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.
[36] K. Georgopoulos,et al. Zinc finger‐mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. , 1996, The EMBO journal.
[37] K. Georgopoulos,et al. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma , 1995, Cell.
[38] A. Sharpe,et al. The ikaros gene is required for the development of all lymphoid lineages , 1994, Cell.